A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Milnacipran 100 And 200 MG Daily in Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Milnacipran 100 And 200 MG Daily in Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2014

At a glance

  • Drugs Milnacipran (Primary)
  • Indications Fibromyalgia
  • Focus Pharmacodynamics
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 04 Sep 2009 Planned number of patients changed from 270 to 321 as reported by ClinicalTrials.gov.
    • 29 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 24 Apr 2008 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top